Symbiotec Pharmalab Limited IPO Analysis, 117-Checkpoint Due Diligence & Valuation Dossier

Issue Size ₹1,757.00 Cr

Price Band ₹938 - ₹988

Lot Size / Min Inv. 15 shares

Estimated Market Cap ₹6,348.20 Cr

Anchor Allocation ₹527.10 Cr (30.0% of Issue)

Offering Dates 24 Aug 2026 - 27 Aug 2026

FAST-ORIENTATION TRIAGE

At a Glance: Fast-Orientation Triage

Mainboard or SME issue?

OK

Mainboard issue (SEBI ICDR Reg 6(1)); Fresh Issue ₹150.00 cr + OFS ₹1,607.00 cr = Total Offer ₹1,757.00 cr.

Listing on BSE and NSE; BSE is Designated Stock Exchange. Implied post-issue mcap ~₹6,348.20 cr at ₹988/share. p.1, 82, 106

Can you explain what the company does in one plain sentence?

OK

R&D-driven biotech & pharma company manufacturing complex corticosteroid and steroidal-hormone APIs, injectables, and CDMO services.

Global leader in corticosteroid (38.2% volume share) & steroidal-hormone APIs (23.8% share). 700 KL fermentation capacity. p.1, 146, 218

Total issue size and post-issue market cap?

OK

Offer price ₹988; Implied P/E of 52.00x (FY26 Diluted EPS ₹19.00), EV/EBITDA 29.01x, P/B 5.35x, post-issue market cap ₹6,348.20 cr.

Peer average P/E is 88.32x (Concord 61.1x, Divi's 87.8x, Cohance 95.0x, Laurus 109.4x). p.106, 149-152

Fresh issue vs OFS - what's the split?

OK

Extreme OFS skew: Fresh Issue ₹150.00 cr (8.54% of offer) vs OFS ₹1,607.00 cr (91.46% of offer).

91.5% of issue proceeds go to exiting PE investors and promoter selling shareholder rather than company growth capital. p.1, 138

Who is selling in the OFS - promoter, PE, or both?

OK

Rosewood Investments (₹988 cr, WACA ₹147.21), India Business Excellence Fund-III (₹475 cr, WACA ₹147.21), and Satwani Holdings LLP (₹144 cr, WACA ₹49.43).

PE investors cashing out at 6.71x their acquisition cost; promoter selling shareholder cashing out at 20.0x WACA. p.1, 138, 160

Is the company profitable, or loss-making?

OK

Profitable with high gross/EBITDA margins, but moderate growth (PAT: FY24 ₹100.06 cr → FY25 ₹96.79 cr → FY26 ₹109.90 cr, CAGR 4.80%).

Revenue: FY24 ₹716.25 cr → FY25 ₹751.55 cr → FY26 ₹869.15 cr (10.16% CAGR); FY26 EBITDA margin 26.59%, Gross margin 63.70%. p.84, 151

Any headline red flag in the first 10 risk factors?

OK

Heavy dependence on API category (96.07% of revenue) & top 10 products (78.96%), and China import reliance for raw materials (23.88% of expenses).

Top customer generates 16.13% and top 5 generate 43.01% of revenue; fermentation scale-up at Ujjain is underway to reduce China reliance. p.29, 35, 37

Auditor qualification or 'emphasis of matter'?

OK

No qualification on restated financials; CARO qualification on pending title registration for SARFAESI leasehold land (₹37.52 cr) and admin audit trail.

Statutory auditor S R B C & CO LLP (EY member firm) since FY24. Audit trail logging for admin access was resolved in March 2026. p.43, 312, 365

Any criminal case / SEBI-RBI action against promoters?

OK

Hostile competitor litigation from Balaji Steroids (₹100 cr defamation suit & writ petition to stall IPO) plus 6 Direct Tax reassessments (₹50.79 cr).

Criminal revision filed by competitor promoter against Anil Satwani seeking to quash 2017 IP theft FIR; total quantified claims ₹150.79 cr (137% of FY26 PAT). p.408-413

IPO P/E vs the peers listed in 'Basis for Offer Price'?

OK

At ₹988 (P/E 52.00x), Symbiotec trades at a discount to rich peer average (88.32x) and Concord (61.07x), but its RoNW (9.48%) and growth lag Divi's and Concord.

High capital intensity and lower unadjusted ROCE (11.56% vs Divi's 20%+) explain the discount; valuation is fair to full given 4.8% PAT CAGR. p.150, 152

Is the use of fresh-issue money clearly growth-oriented?

OK

Limited productivity: Fresh proceeds are small (₹150 cr), with 75% (₹112.50 cr) used for debt repayment and balance for GCP; ₹0 for capex or working capital.

Recent large capex (fermentation & injectables) was already funded via borrowings and internal accruals pre-IPO. p.138-140

Is this within your circle of competence to judge?

OK

Yes, specialized pharmaceutical & biotech API manufacturing with clear metrics: chemistry complexity, DMF/CEP filings, fermentation scale, and margin spreads.

Standard specialty pharma economics governed by US FDA compliance, customer qualification barriers, and vertical integration benefits.

LAYER 1 • STORY & POSITIONING

What The Company Does: Operational & Strategic Architecture

Symbiotec is a specialized biotechnology and pharmaceutical manufacturer focused on complex corticosteroid and steroidal-hormone APIs, complex sterile injectables, and CDMO services. It operates a vertically integrated 'microbe-to-pharmacy' platform spanning multi-step chemical synthesis (up to 400 steps) and industrial-scale fermentation across four facilities in Madhya Pradesh.

#	Checkpoint	Your Finding (Prospectus Data)	Status	Page Ref
1	What does the company do, in one plain sentence?	Symbiotec Pharmalab is an R&D-driven biotechnology and pharma company manufacturing complex corticosteroid and steroidal-hormone APIs, sterile injectables, and CDMO services.	OK	Our Business, p.146, 218
Where in DRHP: Cover, 'Our Business', Industry Overview Why It Matters: If you can't say it simply, neither can the company - and that's telling. Benchmark / Red Flag Trigger: Unexplainable model = step back Exact Citation: Our Business, p.146, 218
2	Operating history & year of incorporation	Incorporated on September 20, 2002 (23+ yrs corporate history), with roots dating back to 1995 when founder Anil Satwani started Symbiotec Laboratories (30+ yrs operating history).	OK	History and Certain Corporate Matters, p.3, 265
Where in DRHP: 'History and Corporate Matters' Why It Matters: A long, consistent track record beats a recently assembled roll-up. Benchmark / Red Flag Trigger: <3 yrs real operating history = caution Exact Citation: History and Certain Corporate Matters, p.3, 265
3	Industry / sub-sector & position in the value chain	Specialty Active Pharmaceutical Ingredients (APIs) & Biotechnology. Positioned across high-barrier niche corticosteroid & steroidal-hormone APIs, sterile injectables, and CDMO.	OK	Industry Overview, p.169, 218
Where in DRHP: 'Industry Overview' Why It Matters: Defines the correct peer set and the normal margin/return profile. Benchmark / Red Flag Trigger: - Exact Citation: Industry Overview, p.169, 218
4	Stated competitive strengths - real or generic?	Deep, high-barrier strengths: global leadership in corticosteroid APIs (38.2% volume share), presence in top 10 molecules, 700 KL fermentation capacity, 43 US FDA DMFs, 23 EDQM CEPs.	OK	Our Strengths, p.146, 221-228
Where in DRHP: 'Our Strengths' Why It Matters: 'Experienced promoters, quality focus' is boilerplate; specifics are real moats. Benchmark / Red Flag Trigger: Only generic strengths = weak moat Exact Citation: Our Strengths, p.146, 221-228
5	Stated growth strategy - concrete or aspirational?	Concrete expansion plans: scaling newly commissioned Ujjain fermentation facility (700 KL total) and Mhow complex injectables plant (20 mn vials), expanding biologics (GLP-1/Insulin).	OK	Our Strategies, p.219, 233-238
Where in DRHP: 'Our Strategies' Why It Matters: Fundable, specific plans beat vague ambition. Benchmark / Red Flag Trigger: Vague strategy = discount the story Exact Citation: Our Strategies, p.219, 233-238
6	Industry tailwinds vs headwinds	Tailwinds: aging population, rising incidence of chronic respiratory/dermatological/oncology conditions, CDMO shift to India. Headwinds: generic API price erosion, China supply risks.	OK	Industry Overview, p.169-217
Where in DRHP: 'Industry Overview', MD&A Why It Matters: Structural growth vs a flat/declining or cyclical-peak market. Benchmark / Red Flag Trigger: Declining/flat industry = headwind Exact Citation: Industry Overview, p.169-217
7	Who commissioned the industry report?	Industry report exclusively commissioned and paid for by the company from Frost & Sullivan (F&S Report dated August 2026).	Watch	Risk Factors, p.22, 60; Our Business, p.218
Where in DRHP: 'Industry Overview' footnotes Why It Matters: Company-paid reports (e.g. CRISIL/F&S) skew optimistic - discount accordingly. Benchmark / Red Flag Trigger: Always company-commissioned Exact Citation: Risk Factors, p.22, 60; Our Business, p.218
8	Is the TAM / market-size claim credible?	Global corticosteroid API market USD 1.25 bn in 2025 (USD 1.62 bn by 2030, CAGR 5.3%); global steroidal hormone API market USD 2.15 bn in 2025. TAM claims appear credible.	OK	Industry Overview, p.175, 185
Where in DRHP: 'Industry Overview' Why It Matters: Sanity-check the addressable market against the company's actual revenue. Benchmark / Red Flag Trigger: Implausibly large TAM = puffery Exact Citation: Industry Overview, p.175, 185
9	Market share and its trend	Global volume market share: 38.2% in corticosteroid APIs and 23.8% in steroidal hormone APIs in FY26. Leadership in Hydrocortisone (80.1%), Testosterone (76.4%), Methylprednisolone (76.0%).	OK	Basis for Offer Price, p.146; Our Business, p.218
Where in DRHP: Industry / Business Why It Matters: Share gains signal real competitiveness; losses signal pressure. Benchmark / Red Flag Trigger: Losing share = flag Exact Citation: Basis for Offer Price, p.146; Our Business, p.218
10	Key competitors named	Global & domestic peers: Sanofi, Pfizer, Aspen Pharmacare, Aarti Drugs, Supriya Lifescience, Neuland Laboratories, Concord Biotech, Divi's Laboratories.	OK	Basis for Offer Price, p.150; Industry Overview, p.205-212
Where in DRHP: 'Competition', Basis for Offer Price Why It Matters: Tells you the genuine peer set for the valuation comparison later. Benchmark / Red Flag Trigger: - Exact Citation: Basis for Offer Price, p.150; Industry Overview, p.205-212

LAYER 2 • ISSUE STRUCTURE & OBJECTS

The IPO Itself: Capital Allocation & Objects Rupee Breakdown

The Offer totals ₹1,757.00 cr, consisting of a small ₹150.00 cr Fresh Issue (8.5%) and a large ₹1,607.00 cr Offer for Sale (91.5%). Private equity funds Rosewood Investments (₹988 cr) and Motilal Oswal PE / IBEF-III (₹475 cr) are cashing out at 6.71x their WACA, while promoter entity Satwani Holdings sells ₹144 cr at 20.0x WACA. Fresh proceeds are strictly used for debt prepayment (₹112.50 cr) and general corporate purposes.

Offering Structure & Tranche Breakup

Offering Parameter / Tranche	Mandate & Allocation	Value & Scale	Strategic Context & Terms
Fresh Issue (Primary Capital)	Growth capital directly reaching balance sheet	₹1,757.00 Cr	Primary equity expansion funding capex, working capital & debt
Offer for Sale (OFS Liquidations)	Secondary liquidity for existing promoters & early funds	OFS Dilution Tranche	Proceeds go entirely to selling shareholders; zero reaches company
Gross Total Issue Size	Aggregate offering scale at upper price band	₹1,757.00 Cr	Total book-building size
Anchor Investor Allocation	Reserved institutional QIB tranche	₹527.10 Cr (30.0% of Issue)	Anchor lock-in: 50% for 30 days, 50% for 90 days post-listing
Pre-IPO WACA Benchmark	Weighted average cost of acquisition for promoters	Disclosed in Basis for Issue Price	Benchmark for pricing fairness and insider multiple markup

Capital Allocation & Objects of the Issue

Object of Offer / Purpose	Allocated Amount	% Share	Execution Timeline
Debt Deleveraging (Prepayment of borrowings)	₹112.50 Cr	75.0%	Scheduled term loan reduction
General Corporate Purposes (GCP)	₹37.50 Cr	25.0%	Working capital & ops
Total Fresh Growth Capital	₹150.00 Cr	100.0%	Balance Sheet Inflow

#	Checkpoint	Your Finding (Prospectus Data)	Status	Page Ref
11	Mainboard or SME issue?	Mainboard public issue under SEBI ICDR Regulation 6(1).	OK	Cover page, p.1; Other Regulatory Disclosures, p.423
Where in DRHP: Cover page Why It Matters: SME = thinner disclosure, lower liquidity, higher risk. Benchmark / Red Flag Trigger: SME = extra caution Exact Citation: Cover page, p.1; Other Regulatory Disclosures, p.423
12	Total issue size (Rs cr)	₹1,757.00 cr (aggregating up to ₹17,570.00 million at upper band / issue price).	OK	Cover page, p.1; The Offer, p.82
Where in DRHP: Cover page / 'The Offer' Why It Matters: Basic sizing of the raise. Benchmark / Red Flag Trigger: - Exact Citation: Cover page, p.1; The Offer, p.82
13	Fresh issue amount (Rs cr)	₹150.00 cr (aggregating up to ₹1,500.00 million).	OK	Objects of the Offer, p.1, 138
Where in DRHP: 'The Offer' Why It Matters: Only the fresh issue brings new money into the company. Benchmark / Red Flag Trigger: - Exact Citation: Objects of the Offer, p.1, 138
14	OFS amount (Rs cr)	₹1,607.00 cr (aggregating up to ₹16,070.00 million).	OK	Objects of the Offer, p.1, 138
Where in DRHP: 'The Offer' Why It Matters: OFS proceeds go to selling shareholders, not the business. Benchmark / Red Flag Trigger: - Exact Citation: Objects of the Offer, p.1, 138
15	Fresh : OFS ratio	Fresh Issue : OFS = 8.54% : 91.46% (Fresh ₹150 cr vs OFS ₹1,607 cr). Heavily skewed towards OFS exit (>70% trigger).	Flag	Objects of the Offer, p.1, 138
Where in DRHP: 'The Offer' Why It Matters: A heavy OFS tilt means the IPO is mostly an exit. Benchmark / Red Flag Trigger: OFS >70% + tiny fresh = flag Exact Citation: Objects of the Offer, p.1, 138
16	Who is selling in the OFS?	Selling Shareholders: Rosewood Investments (up to ₹988 cr), India Business Excellence Fund-III (up to ₹475 cr), and Satwani Holdings LLP (Promoter, up to ₹144 cr). PE exit + promoter monetization.	Flag	Details of OFS, p.1; Objects, p.138
Where in DRHP: 'The Offer' / Selling Shareholders Why It Matters: Promoter exit and PE exit carry very different signals. Benchmark / Red Flag Trigger: Large promoter sell-down = flag Exact Citation: Details of OFS, p.1; Objects, p.138
17	How much does the COMPANY actually receive?	Net Proceeds = ₹150.00 cr minus company's portion of offer expenses (~₹140-145 cr net). Company receives ₹0 from the ₹1,607 cr OFS.	OK	Objects of the Offer, p.138
Where in DRHP: Fresh issue minus issue expenses Why It Matters: This is the real fuel for growth - often far less than the headline. Benchmark / Red Flag Trigger: - Exact Citation: Objects of the Offer, p.138
18	Objects: capex - amount & specificity	₹0.00 cr allocated to plant capex from IPO proceeds. Recent capex on Ujjain fermentation & Mhow injectables already funded via internal accruals and prior debt.	Watch	Objects of the Offer, p.138-140
Where in DRHP: 'Objects of the Offer' Why It Matters: Specific, costed capex is genuine growth spending. Benchmark / Red Flag Trigger: Vague/uncosted capex = flag Exact Citation: Objects of the Offer, p.138-140
19	Objects: debt repayment amount	₹112.50 cr (₹1,125.00 million) allocated for prepayment/scheduled repayment of existing borrowings (75% of gross fresh issue).	OK	Objects of the Offer, p.138, 139
Where in DRHP: 'Objects of the Offer' Why It Matters: Deleveraging is healthy but it is balance-sheet repair, not growth. Benchmark / Red Flag Trigger: High % to debt = repair, not growth Exact Citation: Objects of the Offer, p.138, 139
20	Objects: working capital amount	₹0.00 cr allocated to incremental working capital from IPO proceeds.	N/A	Objects of the Offer, p.138
Where in DRHP: 'Objects of the Offer' Why It Matters: Normal for a growing WC-intensive business; large amounts can signal a stretched cycle. Benchmark / Red Flag Trigger: - Exact Citation: Objects of the Offer, p.138
21	Objects: acquisition - named target or 'future M&A'?	No IPO proceeds earmarked for acquisitions or business takeovers.	N/A	Objects of the Offer, p.138
Where in DRHP: 'Objects of the Offer' Why It Matters: A named, costed target beats a blank cheque for 'inorganic growth'. Benchmark / Red Flag Trigger: Unspecified M&A = flag Exact Citation: Objects of the Offer, p.138
22	General Corporate Purposes (GCP) as % of fresh issue	Balance Net Proceeds (up to ₹37.50 cr, capped at max 25% of Gross Proceeds per SEBI ICDR regulations).	OK	Objects of the Offer, p.138
Where in DRHP: 'Objects of the Offer' Why It Matters: SEBI caps GCP (and unidentified objects). High GCP = undefined use of your money. Benchmark / Red Flag Trigger: Maxed-out / high GCP = flag Exact Citation: Objects of the Offer, p.138
23	Issue expenses as % of the issue	Standard institutional BRLM, legal, and statutory expenses, shared proportionately between Company and Selling Shareholders based on shares offered.	OK	Objects of the Offer, p.142
Where in DRHP: 'Objects of the Offer' Why It Matters: Fees eat into the proceeds that reach the company. Benchmark / Red Flag Trigger: Unusually high = flag Exact Citation: Objects of the Offer, p.142
24	Overall read: growth / debt-repair / exit / mixed?	Primarily an Investor Exit / Monetization issue (91.5% OFS) with modest debt repair (₹112.50 cr); minimal new growth capital raised for the company.	Watch	Objects of the Offer, p.138-140
Where in DRHP: Synthesise the objects Why It Matters: The single most important interpretation of the whole issue. Benchmark / Red Flag Trigger: Pure exit or repair = low enthusiasm Exact Citation: Objects of the Offer, p.138-140
25	Pre-IPO placement done - at what price vs the IPO band?	Rights issue on December 13, 2025 of 6,999,516 equity shares at ₹276.00 per share (aggregating ₹1,931.87 million) to promoters and existing shareholders (3.58x below ₹988 IPO price).	Watch	Capital Structure, p.107; Basis for Offer Price, p.160
Where in DRHP: 'Capital Structure' Why It Matters: A recent placement far below the IPO price signals aggressive pricing. Benchmark / Red Flag Trigger: Big gap below IPO price = flag Exact Citation: Capital Structure, p.107; Basis for Offer Price, p.160
26	WACA - weighted avg cost of acquisition of promoter/investor shares vs IPO price	WACA of selling shareholders: Satwani Holdings LLP ₹49.43 (Offer price ₹988 is 20.0x WACA); Rosewood Investments ₹147.21 (6.71x WACA); India Business Excellence Fund-III ₹147.21 (6.71x WACA).	Watch	Details of OFS, p.1; Basis for Offer Price, p.160
Where in DRHP: 'Basis for Offer Price' Why It Matters: SEBI-mandated. Shows the markup at which insiders are selling to you. Benchmark / Red Flag Trigger: IPO price >> WACA = priced for insiders Exact Citation: Details of OFS, p.1; Basis for Offer Price, p.160

LAYER 3 • BUSINESS QUALITY

Business Quality: Concentration, Retention & Durability

Business durability is anchored by customer stickiness, recurring volume growth, and disciplined operational execution.

Revenue Breakdown & Product Segment Mix

Product / Operating Segment	% Share	Revenue Value
Corticosteroid & Hormone APIs	96.1%	₹835.01 Cr
Complex Sterile Injectables	3.8%	₹33.05 Cr
CDMO & Custom Synthesis Services	0.1%	₹1.09 Cr

Customer & Geographic Concentration Matrix

Counterparty / Customer Tier	Revenue Share (%)	Rupee Amount	Strategic Exposure Note
Corticosteroid & Hormone APIs	96.1%	₹835.01 Cr	Global specialty API formulations
Complex Sterile Injectables & Formulation CDMO	3.9%	₹34.14 Cr	USFDA-compliant injectables
International Export Sales (Europe, USA, RoW)	67.0%	₹582.64 Cr	Export presence in 60+ countries
Domestic India Sales	33.0%	₹286.51 Cr	Domestic pharma formulations OEMs
Top 1 Customer	16.1%	₹130.34 Cr	Multinational generic pharma major
Top 5 Customers	43.0%	₹347.60 Cr	Tier-1 pharmaceutical customers

#

Checkpoint

Your Finding (Prospectus Data)

Status

Page Ref

27

Revenue breakdown by segment / product

FY26 revenue breakdown: Sale of APIs ₹835.01 cr (96.07%), Sale of complex injectables ₹33.05 cr (3.80%), CDMO services ₹1.09 cr (0.13%). Core corticosteroid & hormone APIs dominate.

OK

Risk Factors #1, p.29; Our Business, p.218

28

Top customer as % of revenue

Top Customer accounted for 16.13% of FY26 product revenue (₹130.34 cr), 18.98% in FY25, and 16.21% in FY24. Well below 25-30% red-flag threshold.

Multi-Period Trend Breakdown

FY26	FY25	FY24
product revenue (₹130	, and 16	. Well below 25-30% red-flag threshold

OK

Risk Factors #5, p.34; MD&A, p.381

29

Top 5 customers as % of revenue

Top 5 Customers accounted for 43.01% of FY26 product revenue (₹347.60 cr), 42.27% in FY25, and 48.51% in FY24 (Top 10 = 57.59% in FY26). Moderate customer concentration.

Multi-Period Trend Breakdown

FY26	FY25	FY26
product revenue (₹347	, and 48	)

Watch

Risk Factors #5, p.34; MD&A, p.381

30

Are customer relationships recurring/contracted or order-by-order?

Long-standing recurring relationships (>5-10 yrs) with global pharma majors based on DMF/CEP regulatory filings, though supplies operate via purchase orders rather than long-term take-or-pay contracts.

OK

Risk Factors #14, p.40; Our Business, p.220

31

Recurring / repeat revenue %

Over 85% of revenue derived from repeat customers across Fiscals 2024 - 2026, driven by high vendor switching costs in regulated markets.

OK

Basis for Offer Price, p.146; Our Business, p.220

32

Supplier concentration (top / top-5)

Top 5 suppliers accounted for 21.16% of total expenses in FY26 (₹150.20 cr) (vs 13.97% in FY25, 38.81% in FY24); Top 10 suppliers accounted for 25.50% (₹181.02 cr). Top supplier = 10.96%.

Multi-Period Trend Breakdown

FY26	FY25	FY24
(₹150	, 38	)

OK

Risk Factors #7, p.35

33

Single-source or single raw-material dependency?

High dependency on steroid raw material precursors (Phytosterols, 4-AD, Diosgenin); 23.88% of total expenses (₹169.52 cr) imported from China in FY26 (52.79% in FY24). In-house fermentation is mitigating this.

Watch

Risk Factors #9, p.37

34

Manufacturing footprint - single-plant dependency?

4 specialized manufacturing facilities in Madhya Pradesh: Rau (Indore), Pithampur (SEZ), Ujjain (biotech/CDMO), and Mhow (injectables). Geographically clustered in MP, but diversified across 4 distinct sites.

OK

Risk Factors #6, p.35; Our Business, p.218-219, 238

35

Current capacity utilisation

Chemical synthesis capacity: 584.67 MT (utilization ~70-75%); Fermentation capacity: 700 KL (Ujjain facility newly commissioned, ramping up); Injectables capacity: 20 million vials/yr at Mhow (commenced FY26).

OK

Our Business, p.218-219, 240

36

Geographic concentration of revenue

Well-diversified global footprint: Direct exports 67.04% (₹582.64 cr in FY26 - Europe 29.11%, US 13.12%, Rest of World 24.81%) vs India Domestic 32.96% (₹286.51 cr).

OK

Risk Factors #3, p.34; MD&A, p.391

37

Asset-heavy or asset-light?

Asset-heavy high-tech manufacturing: Net PPE + CWIP + Investment properties = ₹1,184.81 cr as of March 31, 2026 (PPE ₹1,084.39 cr + CWIP ₹64.48 cr + Inv Prop ₹35.94 cr). Gross fixed asset turnover = 1.54x.

OK

Basis for Offer Price, p.152; Financials, p.317

38

Working-capital intensity

Working capital intensity: Operating working capital is ₹275.05 cr (31.65% of revenue in FY26, 38.16% in FY25). Working capital cycle well managed with inventory rationalisation.

Watch

Basis for Offer Price, p.152; MD&A, p.398

39

Distribution model (direct / dealer / online)

Direct B2B sales model to global generic and innovator pharma companies, supported by international regulatory filings and technical marketing teams.

OK

Our Business, p.220, 243

40

Order book / backlog (if relevant)

Operates on short-to-medium term purchase order releases and rolling client forecast schedules tied to registered DMF/CEP dossiers rather than multi-year fixed order backlogs.

OK

Our Business, p.243

41

Cyclicality of the business

Non-cyclical defensive demand driven by essential therapeutic indications (critical care, anti-inflammatory, respiratory, oncology, dermatology, and hormonal replacement).

OK

Industry Overview, p.169-175

42

Entry barriers / moat - real or weak?

Formidable entry barriers / deep moat: Complex steroid synthesis (up to 400 validated steps), 700 KL fermentation scale, 43 US FDA DMFs, 23 EDQM CEPs, and 3-5 year customer qualification cycles.

OK

Our Strengths, p.146, 221-228

43

Key licences / regulatory approvals the business depends on

US FDA cGMP inspection clearances, EU-GMP certification, MFDS Korea approval, WHO-GMP, and MPPCB state pollution control consents to operate across all manufacturing sites.

OK

Our Business, p.218; Government Approvals, p.415-420

44

Technology / obsolescence risk

Low obsolescence risk for core molecules (essential WHO listed therapies); active technological upgrade into biotransformation, continuous flow chemistry, and recombinant biologics (GLP-1/Insulin).

OK

Our Business, p.219, 235

LAYER 4 • FINANCIAL QUALITY

Are The Numbers Real? Multi-Year Forensic Quality Audit

Financial quality is solid on operating cash conversion: FY26 CFO stood at ₹174.59 cr (1.59x PAT), with cumulative 3-year CFO/PAT at 1.33x. Gross margins expanded from 55.2% in FY24 to 63.7% in FY26 as in-house fermentation replaced imported intermediates. Negative 3-year FCF (-₹334 cr) reflects genuine heavy capital expenditure on Ujjain and Mhow facilities (over ₹740 cr spent) rather than poor earnings quality.

Revenue from Operations

+10.2%

₹869.15 Cr

₹716.25 Cr

FY24

₹751.55 Cr

FY25

₹869.15 Cr

FY26

EBITDA & Operating Profit

+14.5%

₹231.97 Cr (26.6%)

₹177.04 Cr (24.5%)

FY24

₹206.11 Cr (27.3%)

FY25

₹231.97 Cr (26.6%)

FY26

Profit After Tax (PAT)

+4.8%

₹109.90 Cr (12.6%)

₹100.06 Cr (13.8%)

FY24

₹96.79 Cr (12.8%)

FY25

₹109.90 Cr (12.6%)

FY26

Cash Flow from Operations (CFO)

Strong CFO

₹174.59 Cr

₹187.50 Cr

FY24

₹47.26 Cr

FY25

₹174.59 Cr

FY26

3-Year Audited Financial Performance Summary

Financial Parameter / Metric	FY24	FY25	FY26	3-Yr CAGR
Revenue from Operations	₹716.25 Cr	₹751.55 Cr	₹869.15 Cr	+10.2%
EBITDA (Operating Profit)	₹177.04 Cr (24.5%)	₹206.11 Cr (27.3%)	₹231.97 Cr (26.6%)	+14.5%
Profit After Tax (PAT)	₹100.06 Cr (13.8%)	₹96.79 Cr (12.8%)	₹109.90 Cr (12.6%)	+4.8%
Operating Cash Flow (CFO)	₹187.50 Cr	₹47.26 Cr	₹174.59 Cr	Strong CFO
Adjusted ROCE (ex-CWIP)	24.59%	27.71%	30.43%	30%+ Adj
Debt-to-Equity (D/E)	0.35x	0.66x	0.34x	Conservative

#

Checkpoint

Your Finding (Prospectus Data)

Status

Page Ref

45

Revenue (3 yrs) and CAGR

Revenue: FY24 ₹716.25 cr → FY25 ₹751.55 cr → FY26 ₹869.15 cr. 3-year CAGR = 10.16% (Core revenue CAGR 13.7% excluding FY24 milestone revenue of ₹44.21 cr).

Multi-Period Trend Breakdown

FY24	FY25	FY26	FY24
₹716	₹751	₹869	milestone revenue of ₹44

OK

Summary Financials, p.84; Basis for Offer Price, p.151

46

Is growth organic or acquisition-driven?

Organic expansion driven by commercialization of new sterile API molecules, expansion of fermentation capacity to 700 KL, and operationalization of the Mhow injectables facility.

OK

Our Business, p.218, 238; MD&A, p.371

47

Gross margin trend (3 yrs)

Gross Margin: FY24 55.18% (₹395.24 cr) → FY25 60.44% (₹454.15 cr) → FY26 63.70% (₹553.69 cr). Significant 850 bps expansion driven by backward integration into fermentation precursors.

Multi-Period Trend Breakdown

FY24	FY25	FY26
55	60	63

OK

Restated Financials, p.318; MD&A, p.371

48

EBITDA and EBITDA-margin trend

EBITDA: FY24 ₹177.04 cr (24.48%) → FY25 ₹206.11 cr (27.26%) → FY26 ₹231.97 cr (26.59%). EBITDA CAGR = 14.47%. Strong and stable margin profile.

Multi-Period Trend Breakdown

FY24	FY25	FY26
₹177	₹206	₹231

OK

Basis for Offer Price, p.151; Summary Financials, p.84

49

Sudden margin spike right before the IPO?

Margins have been consistently strong and stable (EBITDA margin 24.5% to 27.3%, PAT margin 12.6% to 13.8%); no sudden artificial pre-IPO spike.

OK

Basis for Offer Price, p.151

50

PAT and PAT-margin trend

PAT: FY24 ₹100.06 cr (13.83%) → FY25 ₹96.79 cr (12.80%) → FY26 ₹109.90 cr (12.60%). 3-year PAT CAGR = 4.80%. Steady profitability.

Multi-Period Trend Breakdown

FY24	FY25	FY26
₹100	₹96	₹109

OK

Basis for Offer Price, p.151; Restated Financials, p.318

51

Other income as % of PAT

Other Income: FY24 ₹7.09 cr (7.08% of PAT) → FY25 ₹4.43 cr (4.57%) → FY26 ₹3.11 cr (2.83%). Low and declining share of non-operating income.

Multi-Period Trend Breakdown

FY24	FY25	FY26
₹7	₹4	₹3

OK

Restated Financials, p.318; Basis for Offer Price, p.151

52

CFO (operating cash flow) trend

CFO: FY24 ₹187.50 cr → FY25 ₹47.26 cr → FY26 ₹174.59 cr. Strong operating cash flow generation, rebounding sharply in FY26 as working capital stabilized.

Multi-Period Trend Breakdown

FY24	FY25	FY26	FY26
₹187	₹47	₹174	as working capital stabilized

OK

Restated Cash Flow Statement, p.86, 319

53

CFO / PAT (cash conversion), multi-year

CFO/PAT: FY24 1.87x → FY25 0.49x → FY26 1.59x. 3-year cumulative CFO (₹409.35 cr) / cumulative PAT (₹306.74 cr) = 1.33x (133% conversion!). Well above 0.6-0.7x benchmark.

Multi-Period Trend Breakdown

FY24	FY25	FY26
1	0	1

OK

Summary Financials, p.84, 86

54

Was CFO negative in any year?

No. CFO remained healthy and positive in all three fiscals (FY24 ₹187.50 cr, FY25 ₹47.26 cr, FY26 ₹174.59 cr).

Multi-Period Trend Breakdown

FY24	FY25	FY26
₹187	₹47	₹174

OK

Restated Cash Flow Statement, p.86, 319

55

Free cash flow (CFO minus capex)

FCF (CFO - Capex): FY24 -₹22.27 cr → FY25 -₹260.86 cr → FY26 -₹51.13 cr. Cumulative 3-year FCF = -₹334.26 cr due to massive capex on Ujjain (fermentation) & Mhow (injectables) facilities (₹743 cr spent).

Multi-Period Trend Breakdown

FY24	FY25	FY26
₹22	₹260	₹51

Watch

Restated Cash Flow Statement, p.86, 319; Basis for Offer Price, p.152

56

Total debt and net debt

As of March 31, 2026: Total Borrowings ₹387.91 cr (Long-term ₹68.41 cr + Short-term ₹319.50 cr) + Lease liabilities ₹3.08 cr; Cash & bank ₹10.13 cr; Net Debt = ₹380.87 cr (Net Debt/EBITDA = 1.64x).

Watch

Restated Financials, p.317; Basis for Offer Price, p.151

57

Debt / Equity

Debt/Equity ratio: FY24 0.35x → FY25 0.66x → FY26 0.34x. Conservative balance sheet leverage, well below the 1.5-2.0x red-flag threshold.

Multi-Period Trend Breakdown

FY24	FY25	FY26
0	0	0

OK

Restated Financials, p.317; MD&A, p.375

58

Interest coverage (EBIT / interest)

Interest coverage (EBIT / Finance Cost): FY24 19.10x → FY25 10.17x → FY26 7.41x (EBITDA/Finance cost = 9.16x in FY26). Healthy coverage comfortably above 2-3x threshold.

Multi-Period Trend Breakdown

FY24	FY25	FY26	FY26
19	10	7	)

OK

Restated Financials, p.318

59

ROE and trend

Return on Net Worth (RoNW): FY24 13.90% → FY25 11.79% → FY26 9.48% (Weighted Average 10.99%; ROE per KPI table FY26 11.19%). Moderated as equity base expanded via rights issue.

Multi-Period Trend Breakdown

FY24	FY25	FY26	FY26
13	11	9	11

Watch

Basis for Offer Price, p.149, 152

60

ROCE and trend

Return on Capital Employed (ROCE): FY24 14.03% → FY25 11.80% → FY26 11.56%. Adjusted ROCE (excluding CWIP / newly commissioned idle capex): FY24 24.59% → FY25 27.71% → FY26 30.43%.

Multi-Period Trend Breakdown

FY24	FY25	FY26	FY24	FY25	FY26
14	11	11	24	27	30

OK

Basis for Offer Price, p.152

61

ROCE vs cost of capital

Reported FY26 ROCE of 11.56% sits around cost of capital (~11-12%), but Adjusted ROCE of 30.43% demonstrates robust core capital efficiency once new assets reach target utilization.

Watch

Basis for Offer Price, p.152

62

Debtor (receivable) days and trend

Debtor Days (on revenue): FY24 64 days (₹125.67 cr) → FY25 85 days (₹175.65 cr) → FY26 83 days (₹197.60 cr). Stable collection cycle aligned with global pharmaceutical export terms.

Multi-Period Trend Breakdown

FY24	FY25	FY26
64 days (₹125	85 days (₹175	83 days (₹197

OK

Restated Financials, p.317, 318

63

Inventory days and trend

Inventory Days (on revenue): FY24 171 days (₹335.79 cr) → FY25 127 days (₹261.45 cr) → FY26 99 days (₹236.88 cr) (or 274 days on COGS). Meaningful inventory efficiency achieved.

Multi-Period Trend Breakdown

FY24	FY25	FY26
171 days (₹335	127 days (₹261	99 days (₹236

OK

Restated Financials, p.317, 318

64

Payable days and trend

Payable Days (on revenue): FY24 116 days (₹227.61 cr) → FY25 43 days (₹88.50 cr) → FY26 58 days (₹138.33 cr) (or 160 days on COGS). Normalized creditor payment cycle.

Multi-Period Trend Breakdown

FY24	FY25	FY26
116 days (₹227	43 days (₹88	58 days (₹138

OK

Restated Financials, p.317, 318

65

Cash conversion cycle

Cash Conversion Cycle (on revenue): FY24 119 days → FY25 169 days → FY26 124 days. Working capital cycle improved by 45 days in FY26.

OK

Restated Financials, p.317, 318

66

Contingent liabilities vs net worth

Contingent Liabilities: ₹0.00 cr (Nil) as per Ind AS 37 as of March 31, 2026. Zero contingent claims against Net Worth of ₹1,149.59 cr.

OK

Summary of Contingent Liabilities, p.90; MD&A, p.398

67

Capex history vs proposed capex

Historical Capex: FY24 ₹176.66 cr, FY25 ₹392.90 cr, FY26 ₹237.31 cr (total ₹806.87 cr). Major expansion phase completed; ₹0 allocated from IPO proceeds for future capex.

Multi-Period Trend Breakdown

FY24	FY25	FY26
₹176	₹392	₹237

OK

Basis for Offer Price, p.152; Objects, p.138

68

Dividend history

No dividends declared or paid in Fiscals 2024, 2025, or 2026. Entire cash retained to fund plant expansion at Ujjain and Mhow.

OK

Dividend Policy, p.308

69

Standalone vs consolidated divergence

Standalone and Consolidated figures are virtually identical (FY26 Standalone Rev ₹869.15 cr, PAT ₹109.90 cr). Subsidiaries are 100% owned operational/biotech units.

OK

Restated Financials, p.309; Other Financial Info, p.366

70

Material restatement adjustments?

No material restatement adjustments; restatement reconciles cleanly to audited financial statements with standard regroupings (Annexure VII Part A).

OK

Restated Financials, p.365

71

Auditor qualifications / emphasis of matter

Clean audit opinion on restated summary statements. CARO qualification noted on pending registration of title deed for SARFAESI leasehold land (₹37.52 cr) and admin audit trail (fixed March 2026).

Watch

Risk Factors #18, p.43; Auditor's Report, p.312, 365

72

Aggressive revenue-recognition policy?

Standard Ind AS 115 revenue recognition policy based on transfer of control and dispatch/delivery per Incoterms. No aggressive bill-and-hold practices.

OK

Significant Accounting Policies, p.327

LAYERS 5 & 6 • GOVERNANCE & RPT

Governance Architecture & Related Party Transactions

Anil Satwani has led the business for over 30 years with zero promoter share pledge. The board is structurally sound with 62.5% independent directors (5 of 8) and reputable statutory auditor S R B C & CO LLP (EY). Consolidated RPTs are strictly confined to managerial remuneration (~₹11.58 cr to promoter family = 10.5% of PAT) with zero outside related party trading. Minor past non-compliance regarding company secretary appointment (2005-2014) is pending compounding before NCLT.

Pre & Post-Issue Shareholding Structure

Shareholder Category / Promoter	Pre-IPO %	Post-IPO %	Pledge Status	Statutory Lock-in
-	-	-	Nil	Standard
-	-	-	Nil	Standard
-	-	-	Nil	Standard

#	Checkpoint	Your Finding (Prospectus Data)	Status	Page Ref
73	Promoter background and track record	Promoter Anil Satwani (CMD) has over 30 years experience in steroid & hormone chemistry. Clean regulatory record, though competitor has filed retaliatory litigation.	OK	Our Management, p.278; Our Promoters, p.301
Where in DRHP: 'Our Promoters', 'Management' Why It Matters: The quality and integrity of stewardship. Benchmark / Red Flag Trigger: Prior failure/fraud = flag Exact Citation: Our Management, p.278; Our Promoters, p.301
74	Promoter holding pre-IPO	Promoters hold 18,073,104 Equity Shares (28.80%), and Promoter Group holds 22,841,312 shares (36.41%) of pre-issue fully diluted capital.	OK	Capital Structure, p.106, 123
Where in DRHP: 'Capital Structure' Why It Matters: Skin in the game today. Benchmark / Red Flag Trigger: - Exact Citation: Capital Structure, p.106, 123
75	Promoter holding post-IPO	Will dilute slightly to ~32-34% post-issue and Satwani Holdings LLP OFS (~1.46 mn shares), while PE investors Rosewood and IBEF-III sell ~14.8 mn shares. Promoters retain management control.	OK	Capital Structure, p.106, 123
Where in DRHP: 'Capital Structure' Why It Matters: Alignment going forward. Benchmark / Red Flag Trigger: Very low post-IPO = misalignment Exact Citation: Capital Structure, p.106, 123
76	Promoter share pledge	Zero (Nil) promoter shares pledged or encumbered as of the date of the RHP.	OK	Capital Structure, p.106, 123
Where in DRHP: 'Capital Structure', Risk Factors Why It Matters: Pledging signals financial stress. Benchmark / Red Flag Trigger: Any meaningful pledge = flag Exact Citation: Capital Structure, p.106, 123
77	Promoter / KMP remuneration vs PAT and peers	FY26 Promoter Remuneration: Anil Satwani ₹8.09 cr, Sushil Satwani ₹2.25 cr, relatives ₹1.24 cr (Total promoter family remuneration ~₹11.58 cr = 10.54% of FY26 PAT). Fair but on the higher side.	Watch	Summary of RPTs, p.91; Management, p.283
Where in DRHP: 'Management' Why It Matters: Cash extraction relative to profits. Benchmark / Red Flag Trigger: High pay vs PAT = flag Exact Citation: Summary of RPTs, p.91; Management, p.283
78	Group structure - complex / circular / many entities?	Clean corporate structure: 4 direct wholly owned operating subsidiaries (Knovea, Symbiotec Zenfold, Symbiotec Biologics, Navisci Pte) and 1 corporate promoter (Satwani Holdings LLP). No web of shell entities.	OK	History and Corporate Matters, p.265; Group Companies, p.421
Where in DRHP: 'Our Group Companies' Why It Matters: Complexity is where value and leakage hide. Benchmark / Red Flag Trigger: Complex web = flag Exact Citation: History and Corporate Matters, p.265; Group Companies, p.421
79	Auditor - reputable? Recent change or resignation?	S R B C & CO LLP (EY member firm) has served as statutory auditor since FY24. No auditor resignation prior to the IPO.	OK	General Information, p.95; Auditor's Report, p.312
Where in DRHP: 'Auditors', history Why It Matters: Audit credibility and any pre-IPO churn. Benchmark / Red Flag Trigger: Resignation before IPO = flag Exact Citation: General Information, p.95; Auditor's Report, p.312
80	CFO / KMP churn before the IPO	Stable key management: Salil Jain (Company Secretary & Compliance Officer) with company since 2018; Raghavender Ramachandran (CFO) with company since 2021. No disruptive pre-IPO KMP exits.	OK	Our Management, p.285-288
Where in DRHP: 'Management', history Why It Matters: Instability in key finance roles before listing. Benchmark / Red Flag Trigger: CFO exit pre-IPO = flag Exact Citation: Our Management, p.285-288
81	Board: proportion of independent directors	8 Board members: 1 Executive CMD (Anil Satwani), 2 Nominee Directors (PE investors: Rohit Mantri, Dhananjay Mungale), and 5 Independent Directors (62.5% independent board, 1 woman director).	OK	Our Management, p.276-278
Where in DRHP: 'Management' Why It Matters: Strength of independent oversight. Benchmark / Red Flag Trigger: Below norms = flag Exact Citation: Our Management, p.276-278
82	Independent-director credentials - real or token?	Strong independent credentials: Sunita Kishnani (PhD, CMO, award-winning marketing professional), Pratik Patel (MD Jash Engineering), Pramod Kasat (ex-Credit Suisse/IndusInd), Richard Kenny, B.M. Maheshwari.	OK	Our Management, p.278-281
Where in DRHP: Director bios Why It Matters: Whether oversight is actually effective. Benchmark / Red Flag Trigger: Token / related IDs = flag Exact Citation: Our Management, p.278-281
83	ESOP / outstanding options - dilution overhang	Symbiotec ESOP Scheme 2021: 24,570 vested options unexercised. Negligible dilution overhang (<0.05% of pre-issue capital).	OK	Capital Structure, p.106, 133
Where in DRHP: 'Capital Structure' Why It Matters: Future dilution of your stake. Benchmark / Red Flag Trigger: Large unvested pool = caution Exact Citation: Capital Structure, p.106, 133
84	Lock-in: promoter and anchor / pre-IPO investors	20% post-issue promoter shareholding locked in for 18 months; balance promoter shares locked in for 6 months. Non-promoter pre-IPO shares locked in for 6 months. Anchor investors locked in 30/90 days.	OK	Capital Structure, p.110-112
Where in DRHP: 'Capital Structure' Why It Matters: Share supply that hits the market post-listing. Benchmark / Red Flag Trigger: Big near-term unlocks = caution Exact Citation: Capital Structure, p.110-112
85	Past corporate-governance issues / regulatory strictures	Compounding application pending before NCLT Indore for past failure to appoint a whole-time company secretary between 2005 and 2014 under Section 383A of Companies Act, 1956.	Watch	Risk Factors #19, p.43; Outstanding Litigation, p.408
Where in DRHP: Risk Factors, Litigation Why It Matters: A pattern of past behaviour. Benchmark / Red Flag Trigger: Any history = flag Exact Citation: Risk Factors #19, p.43; Outstanding Litigation, p.408

#	Checkpoint	Your Finding (Prospectus Data)	Status	Page Ref
86	Sales to related parties (% of revenue)	0.00% (Nil) of consolidated revenue from operations. All inter-company sales (₹9.55 cr in FY26) are with 100% subsidiaries and fully eliminated on consolidation.	OK	Summary of RPTs, p.91, 92
Where in DRHP: RPT note Why It Matters: Revenue propped up by group entities? Benchmark / Red Flag Trigger: High % = flag Exact Citation: Summary of RPTs, p.91, 92
87	Purchases from related parties (% of costs)	0.00% (Nil) of consolidated costs. Inter-company purchases from subsidiaries (₹11.10 cr in FY26) are 100% eliminated on consolidation.	OK	Summary of RPTs, p.91, 92
Where in DRHP: RPT note Why It Matters: A channel to manipulate margins. Benchmark / Red Flag Trigger: High % = flag Exact Citation: Summary of RPTs, p.91, 92
88	Loans / advances to promoter or related entities	No loans or advances outstanding to promoters or promoter-controlled external entities. Inter-company loans are between parent and wholly owned subsidiaries for funding plant capex.	OK	Summary of RPTs, p.91-93
Where in DRHP: RPT note Why It Matters: Company cash diverted to insiders. Benchmark / Red Flag Trigger: Any sizeable loan out = flag Exact Citation: Summary of RPTs, p.91-93
89	Rent / royalty / brand fees paid to related parties	Zero brand royalty, franchise fees, or extraction payments made to promoters or related parties.	OK	Summary of RPTs, p.91
Where in DRHP: RPT note Why It Matters: Recurring cash extraction from the company. Benchmark / Red Flag Trigger: Royalty to promoter = flag Exact Citation: Summary of RPTs, p.91
90	Outstanding RPT balances (receivable / payable)	Minimal year-end balances with outside related parties (only regular employee remuneration payables).	OK	Summary of RPTs, p.91
Where in DRHP: RPT note Why It Matters: Money stuck with related parties. Benchmark / Red Flag Trigger: Large outstanding = flag Exact Citation: Summary of RPTs, p.91
91	RPT trend over 3 years	Stable and minimal non-remuneration related party dealings over the 3-year period.	OK	Summary of RPTs, p.91-93
Where in DRHP: RPT note Why It Matters: Rising reliance on related-party dealings. Benchmark / Red Flag Trigger: Increasing trend = flag Exact Citation: Summary of RPTs, p.91-93
92	Disclosed at arm's length? Pricing basis?	Company confirms all related party transactions are executed in the ordinary course of business and on an arm's length basis.	OK	Summary of RPTs, p.91; Financial Note 33, p.355
Where in DRHP: RPT note Why It Matters: Whether terms are fair to minority shareholders. Benchmark / Red Flag Trigger: 'At cost'/unclear basis = scrutinise Exact Citation: Summary of RPTs, p.91; Financial Note 33, p.355
93	Overall RPT concern level (Low / Medium / High)	Low. Consolidated RPTs are strictly confined to standard managerial remuneration with zero related-party leakage.	OK	Summary of RPTs, p.91-94
Where in DRHP: Synthesise this layer Why It Matters: Your single judgment on related-party risk. Benchmark / Red Flag Trigger: - Exact Citation: Summary of RPTs, p.91-94

LAYER 7 • LITIGATION & REGULATORY

Litigation, Tax Disputes & Materiality Sizing

Outstanding legal proceedings represent standard commercial and tax disputes with low aggregate materiality relative to net worth.

Outstanding Legal & Tax Dispute Summary

Litigation / Regulatory Category	Case Count	Quantifiable Exposure	Materiality & Balance Sheet Risk
Direct Tax Reassessment Appeals	1	₹50.79 Cr	Evaluated
Competitor Defamation Suit	1	₹100.00 Cr	Evaluated
USFDA / Regulatory Inspections	1	₹0.00 Cr	Evaluated

#	Checkpoint	Your Finding (Prospectus Data)	Status	Page Ref
94	Criminal cases against promoters / directors	Criminal revision application filed by competitor promoter Prem Aldasani (Balaji Steroids) in May 2026 under BNSS Sec 528 seeking to quash Symbiotec's 2017 FIR for IP theft. No conviction or fraud charges against promoters.	Watch	Outstanding Litigation, p.407, 412
Where in DRHP: 'Outstanding Litigation' Why It Matters: An integrity red flag that can override the numbers. Benchmark / Red Flag Trigger: Any = serious flag Exact Citation: Outstanding Litigation, p.407, 412
95	Material civil / commercial cases - company	Competitor Balaji Steroids filed a civil suit in July 2026 claiming ₹100.00 cr (₹1,000 mn) damages for alleged defamatory offer document disclosures, and an MP High Court Writ Petition attempting to halt the IPO.	Watch	Outstanding Litigation, p.408, 412
Where in DRHP: 'Outstanding Litigation' Why It Matters: Direct business and financial risk. Benchmark / Red Flag Trigger: - Exact Citation: Outstanding Litigation, p.408, 412
96	Direct + indirect tax disputes and amounts	6 Direct Tax cases aggregating ₹50.79 cr (₹507.92 mn) pending under Section 148A reassessment notices for AY21 to AY25. Indirect tax disputes: Nil.	Watch	Outstanding Litigation, p.408
Where in DRHP: 'Outstanding Litigation' Why It Matters: Contingent cash outflows. Benchmark / Red Flag Trigger: Large vs PAT = flag Exact Citation: Outstanding Litigation, p.408
97	Regulatory / statutory actions (SEBI, RBI, environmental, labour)	NCLT Indore compounding application pending for Section 383A past non-compliance (2005-2014 CS appointment). No active SEBI, RBI, or environmental shutdown orders.	Watch	Risk Factors #19, p.43; Outstanding Litigation, p.408
Where in DRHP: 'Outstanding Litigation' Why It Matters: Signals compliance culture. Benchmark / Red Flag Trigger: Active actions = flag Exact Citation: Risk Factors #19, p.43; Outstanding Litigation, p.408
98	Total quantifiable amount involved	Total quantifiable amount: ₹150.79 cr (₹50.79 cr direct tax reassessments + ₹100.00 cr competitor defamation suit).	Watch	Outstanding Litigation, p.408-413
Where in DRHP: Litigation summary Why It Matters: Sizing the aggregate exposure. Benchmark / Red Flag Trigger: - Exact Citation: Outstanding Litigation, p.408-413
99	Materiality vs PAT and net worth	Quantified litigation (₹150.79 cr) represents 137.2% of FY26 PAT (₹109.90 cr) and 13.1% of Net worth (₹1,149.59 cr). Tax claims alone (₹50.79 cr) represent 46.2% of PAT. Moderate-to-high materiality.	Watch	Outstanding Litigation, p.408-413; Restated Financials, p.317, 318
Where in DRHP: Compare Why It Matters: Whether the exposure is survivable. Benchmark / Red Flag Trigger: Multiple of PAT / net worth = flag Exact Citation: Outstanding Litigation, p.408-413; Restated Financials, p.317, 318
100	Any case threatening a key licence or the business model?	No case threatens core cGMP manufacturing licences, US FDA DMFs, EDQM CEPs, or ongoing factory operations.	OK	Outstanding Litigation, p.408-415
Where in DRHP: Litigation, Risk Factors Why It Matters: Existential risk to operations. Benchmark / Red Flag Trigger: Yes = serious flag Exact Citation: Outstanding Litigation, p.408-415

LAYER 8 • VALUATION & PEER BENCHMARK

Valuation: Peer Comparison & Multiples Benchmark

Valuation benchmark indicates competitive pricing relative to listed industry peers and forward earnings power.

Listed Industry Peer Valuation Benchmark

Company Name / Peer Benchmark	P/E (x)	EV/EBITDA	P/S (x)	ROE (%)	ROCE (%)	YoY Growth	PAT Margin
Symbiotec Pharmalab Limited	32.4x	18.5x	-	-	30.4%	-	-
Divi's Laboratories Limited	78.5x	48.2x	-	-	21.4%	-	-
Supriya Lifescience Limited	31.8x	18.2x	-	-	22.8%	-	-
Aarti Drugs Limited	24.2x	13.5x	-	-	14.5%	-	-
API Peer Composite	44.8x	26.6x	-	-	19.6%	-	-

#	Checkpoint	Your Finding (Prospectus Data)	Status	Page Ref
101	IPO P/E (post-issue, upper band)	At ₹988 Offer Price: IPO P/E is 52.00x on FY26 Diluted EPS (₹19.00) and 51.73x on Basic EPS (₹19.10).	Watch	Basis for Offer Price, p.149, 150
Where in DRHP: Basis for Offer Price / compute Why It Matters: The headline earnings multiple you're paying. Benchmark / Red Flag Trigger: - Exact Citation: Basis for Offer Price, p.149, 150
102	Peer P/E - and is the peer set fair or cherry-picked?	Peer P/E range in DRHP: Concord Biotech (61.07x), Divi's Labs (87.80x), Cohance (95.02x), Laurus Labs (109.36x); Peer average P/E = 88.32x. Rich peer set of large-cap pharma/biotech leaders.	Watch	Basis for Offer Price, p.150
Where in DRHP: 'Basis for Offer Price' Why It Matters: Companies pick flattering peers; rebuild the set yourself. Benchmark / Red Flag Trigger: Cherry-picked rich peers = flag Exact Citation: Basis for Offer Price, p.150
103	EV / EBITDA vs peers	Symbiotec FY26 EBITDA is ₹231.97 cr. At ₹988, implied Enterprise Value is ₹6,729.07 cr -> EV/EBITDA is 29.01x (peer Concord ~32x, Divi's ~55x, API sector ~16-18x).	Watch	Basis for Offer Price, p.150, 151
Where in DRHP: Compute / peers Why It Matters: A capital-structure-neutral comparison. Benchmark / Red Flag Trigger: - Exact Citation: Basis for Offer Price, p.150, 151
104	Price / Sales (especially if loss-making)	FY26 Revenue is ₹869.15 cr. At implied Market Cap of ₹6,348.20 cr, Price/Sales (P/S) multiple is 7.30x.	Watch	Basis for Offer Price, p.150, 151
Where in DRHP: Compute Why It Matters: The relevant lens for unprofitable companies. Benchmark / Red Flag Trigger: Aggressive P/S on losses = flag Exact Citation: Basis for Offer Price, p.150, 151
105	Price / Book	FY26 Pre-issue NAV is ₹184.69. At ₹988 Offer Price, Price/Book (P/B) multiple is 5.35x.	Watch	Basis for Offer Price, p.150
Where in DRHP: Compute Why It Matters: Relevant for asset-heavy and financial businesses. Benchmark / Red Flag Trigger: - Exact Citation: Basis for Offer Price, p.150
106	Implied market cap at IPO	Post-issue paid-up shares: 64,253,069 equity shares. At ₹988 Offer Price, Implied Market Cap is ₹6,348.20 cr (₹63,482.03 million).	OK	Capital Structure, p.106; Basis for Offer Price, p.150
Where in DRHP: Compute Why It Matters: The absolute size of what you're buying. Benchmark / Red Flag Trigger: - Exact Citation: Capital Structure, p.106; Basis for Offer Price, p.150
107	ROE vs peers	Symbiotec FY26 RoNW is 9.48% (ROE 11.19%), trailing Divi's (16.50%), Laurus (16.80%), and Concord (14.00%), but ahead of Cohance (7.00%).	Watch	Basis for Offer Price, p.150, 152
Where in DRHP: Compare Why It Matters: Does quality justify any premium? Benchmark / Red Flag Trigger: Premium + lower ROE = flag Exact Citation: Basis for Offer Price, p.150, 152
108	ROCE vs peers	Symbiotec FY26 reported ROCE of 11.56% lags Divi's (20%+), but its Adjusted ROCE of 30.43% (excluding CWIP) is competitive with top tier CDMO/biotech peers.	OK	Basis for Offer Price, p.150, 152
Where in DRHP: Compare Why It Matters: Capital efficiency relative to price. Benchmark / Red Flag Trigger: - Exact Citation: Basis for Offer Price, p.150, 152
109	Growth vs peers	Symbiotec 3-yr Revenue CAGR (10.16%) and PAT CAGR (4.80%) lag fast-growing peers, though FY26 revenue accelerated to 15.65% as new capacities came online.	Watch	Basis for Offer Price, p.150, 151
Where in DRHP: Compare Why It Matters: Does faster growth justify the premium? Benchmark / Red Flag Trigger: Premium + slower growth = flag Exact Citation: Basis for Offer Price, p.150, 151
110	Margins vs peers	Symbiotec FY26 EBITDA margin (26.59%) and Gross margin (63.70%) are superior to general API peers and comparable to Concord Biotech (30%) and Divi's (32%).	OK	Basis for Offer Price, p.150, 151
Where in DRHP: Compare Why It Matters: Quality of earnings relative to price. Benchmark / Red Flag Trigger: - Exact Citation: Basis for Offer Price, p.150, 151
111	IPO price vs WACA / pre-IPO placement (the markup)	Offer price ₹988 is 20.0x promoter WACA (₹49.43), 6.71x PE investors' WACA (₹147.21), and 3.58x the Dec 2025 rights issue price (₹276.00). High markup for public investors.	Watch	Details of OFS, p.1; Basis for Offer Price, p.160
Where in DRHP: Basis for Offer Price Why It Matters: What insiders paid versus what you're paying. Benchmark / Red Flag Trigger: Large multiple over WACA = flag Exact Citation: Details of OFS, p.1; Basis for Offer Price, p.160
112	Is the premium justified by ROCE / ROE / growth / margins?	Valuation multiple (P/E 52.0x, EV/EBITDA 29.0x) is partly supported by global niche dominance (38.2% steroid API share) and 700 KL fermentation moat, but constrained by modest historical PAT CAGR (4.8%) and RoNW (9.5%).	Watch	Basis for Offer Price, p.150-152
Where in DRHP: Synthesise Why It Matters: The core valuation verdict. Benchmark / Red Flag Trigger: Premium unsupported by quality = flag Exact Citation: Basis for Offer Price, p.150-152
113	What growth does the price implicitly assume?	At ₹988 (P/E 52.0x), the valuation assumes newly commissioned Ujjain fermentation and Mhow injectables facilities deliver an immediate acceleration in earnings to 20-25%+ PAT CAGR over FY26 - 29.	Watch	Basis for Offer Price, p.150; Our Business, p.218
Where in DRHP: Reverse the multiple / judgment Why It Matters: Are the embedded expectations realistic? Benchmark / Red Flag Trigger: Heroic assumptions = flag Exact Citation: Basis for Offer Price, p.150; Our Business, p.218

LAYER 9 • STATED RISK ADMISSIONS

In The Company's Own Words: Stated Risk Admissions

Management highlights key operational sensitivities including raw material pricing, client concentration, and execution timelines.

#	Checkpoint	Your Finding (Prospectus Data)	Status	Page Ref
114	Top 5 risk factors the company itself lists	(1) API product revenue concentration (96.07%) & top 5 APIs (62.27%); (2) Periodic regulatory inspections by US FDA and other health authorities; (3) Heavy export reliance (67.04% international); (4) US market exposure (13.12%); (5) Key customer concentration (Top 10 = 57.59%).	Watch	Risk Factors #1-#5, p.28-34
Where in DRHP: 'Risk Factors' Why It Matters: Management's own stated worries - read them first. Benchmark / Red Flag Trigger: - Exact Citation: Risk Factors #1-#5, p.28-34
115	Any genuine dealbreaker buried in boilerplate?	Raw material import dependence on China (23.88% of total expenses), pending hostile competitor litigation/writ petition by Balaji Steroids seeking forensic audit (p.413), and Section 148A tax reassessments (₹50.79 cr).	Watch	Risk Factors #9, p.37; Outstanding Litigation, p.408, 413
Where in DRHP: 'Risk Factors' Why It Matters: The serious risks hide among generic ones; find them. Benchmark / Red Flag Trigger: - Exact Citation: Risk Factors #9, p.37; Outstanding Litigation, p.408, 413
116	Quantified risks (e.g. 'X would cut revenue by Y%')	China raw material imports: ₹169.52 cr (23.88% of expenses); Top 10 customers: ₹465.47 cr (57.59% of sales); Direct tax exposure: ₹50.79 cr; Competitor litigation claim: ₹100.00 cr.	Watch	Risk Factors #5, #7, #9, p.34-37; Outstanding Litigation, p.408, 409
Where in DRHP: 'Risk Factors' Why It Matters: The risks management bothered to quantify are usually the real ones. Benchmark / Red Flag Trigger: - Exact Citation: Risk Factors #5, #7, #9, p.34-37; Outstanding Litigation, p.408, 409
117	Going-concern or liquidity language anywhere?	No going-concern qualification or explanatory paragraph in statutory auditor report. Liquidity supported by positive operating cash flows (FY26 CFO ₹174.59 cr) and working capital credit lines.	OK	Auditor's Report, p.312; Restated Financials, p.319
Where in DRHP: Risk Factors / Auditor Why It Matters: A direct signal of survival risk. Benchmark / Red Flag Trigger: Any going-concern language = serious flag Exact Citation: Auditor's Report, p.312; Restated Financials, p.319

AUDIT TALLY • 117-CHECKPOINT RISK MATRIX

Red-Flag Dashboard: 117-Checkpoint Audit Tally

79

Checkpoints Clean (OK)

34

Watchlist Monitor Rows

2

High-Severity Red Flags

117

Total Forensic Checkpoints

L1 Story & Positioning

9 1 0

L2 Issue Structure & Objects

8 4 2

L3 Business Quality

15 3 0

L4 Financial Quality

23 5 0

L5 Governance

11 2 0

L6 Related Party Transactions

8 0 0

L7 Litigation & Regulatory

1 6 0

L8 Valuation

3 10 0

L9 The Company's Own Risk Factors

1 3 0

Layer 1: Story & Positioning

9 OK 1 Watch 0 Flag

Layer 2: Issue Structure & Objects

8 OK 4 Watch 2 Flag

Layer 3: Business Quality

15 OK 3 Watch 0 Flag

Layer 4: Financial Quality

23 OK 5 Watch 0 Flag

Layer 5: Governance

11 OK 2 Watch 0 Flag

Layer 6: Related Party Transactions

8 OK 0 Watch 0 Flag

Layer 7: Litigation & Regulatory

1 OK 6 Watch 0 Flag

Layer 8: Valuation

3 OK 10 Watch 0 Flag

Layer 9: The Company's Own Risk Factors

1 OK 3 Watch 0 Flag

How To Read This Risk Matrix

These tallies reflect the 117 checkpoints evaluated across the 9 analytical layers. In institutional forensic analysis, clusters matter far more than isolated totals: an amber or red flag in Layer 4 (Financial Quality) or Layer 5 (Governance) carries exponentially higher structural weight than narrative observations in Layer 1. Always evaluate flags against company peers and industry context.

Statutory Educational Compliance & Analyst Disclaimer

This research report is prepared strictly for educational and informational purposes only and does not constitute financial, investment, legal, tax, or underwriting advice. Neither IPrOspecta nor the author (Tanish Vijayvargiya) is a SEBI-registered Research Analyst or SEBI-registered Investment Adviser under the SEBI (Research Analysts) Regulations, 2014 or SEBI (Investment Advisers) Regulations, 2013.

Nothing in this publication should be construed as an explicit or implicit recommendation, solicitation, endorsement, or offer to buy, sell, subscribe to, or hold any security, IPO application, or financial product. Prospective investors must conduct their own independent due diligence, carefully review the complete Red Herring Prospectus (RHP) / Draft Red Herring Prospectus (DRHP) filed with SEBI and the stock exchanges, and consult a qualified, SEBI-registered financial adviser before committing capital.

Position Disclosure: The author and IPrOspecta maintain zero commercial affiliation with the issuer company, book running lead managers, selling shareholders, or syndicate underwriters. All opinions expressed represent personal analytical frameworks.